Key facts
- This page summarizes Deep Track Capital, LP's Form 4 filing for NEKTAR THERAPEUTICS (NKTR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 13 May 2024, 16:36.
Deep Track Capital, LP - 10 May 2024 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- NKTR
- Reported as of
- 10 May 2024
- Net transaction value
- -$99,630
- SEC form
- 4
- Accepted by SEC
- 13 May 2024, 16:36:00 UTC
- Prior SEC filing
- 14 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- Deep Track Capital, LP /s/ David Kroin, Name: David Kroin, Title: Managing Member of the General Partner of the Investment Adviser
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Deep Track Capital, LP filed Form 4 for NEKTAR THERAPEUTICS (NKTR) on 13 May 2024.
Change
- Previous filing in this sequence was filed on 14 Mar 2024.
- Current net transaction value: -$99,630.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
NKTR
transaction
Common Stock
Sale
- Transaction value
- $99,630
- Shares
- -56,000
- Change %
- -0.3%
- Price
- $1.78
- Shares after
- 18,344,000
- Date
- 10 May 2024
- Ownership
- See Footnote
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Deep Track Capital, LP is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 2 footnotes
Footnote F1
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.745 to $1.81, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes to this Form 4.
Footnote F2
Represents securities held by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, LP. is the investment manager of Deep Track Biotechnology Master Fund, Ltd. Mr. David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, LP., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Biotechnology Master Fund, Ltd. Deep Track Capital, L.P. and Mr. Kroin disclaim beneficial ownership of such shares except to the extent of their respective pecuniary interests.